NASDAQ:IMNP - Immune Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0185 0.00 (-3.14 %)
(As of 12/13/2018 03:06 AM ET)
Previous Close$0.0191
Today's Range$0.0176 - $0.02
52-Week Range$0.0120 - $0.8250
Volume318,446 shs
Average Volume860,346 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Receive IMNP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMNP
Previous SymbolOTCMKTS:EPCT
CUSIPN/A
Phone201-464-2677

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares56,070,000
Market Cap$0.00
OptionableNot Optionable

Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) announced its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.05. View Immune Pharmaceuticals' Earnings History.

What price target have analysts set for IMNP?

1 equities research analysts have issued 1 year target prices for Immune Pharmaceuticals' shares. Their predictions range from $2.00 to $2.00. On average, they anticipate Immune Pharmaceuticals' share price to reach $2.00 in the next year. This suggests a possible upside of 10,710.8% from the stock's current price. View Analyst Price Targets for Immune Pharmaceuticals.

What is the consensus analysts' recommendation for Immune Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immune Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Immune Pharmaceuticals.

Has Immune Pharmaceuticals been receiving favorable news coverage?

News coverage about IMNP stock has trended very positive on Thursday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Immune Pharmaceuticals earned a news sentiment score of 3.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Immune Pharmaceuticals' key competitors?

Who are Immune Pharmaceuticals' key executives?

Immune Pharmaceuticals' management team includes the folowing people:
  • Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
  • Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)
  • Mr. Christine J. Petraglia, Director of Investor Relations
  • Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
  • Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc

How do I buy shares of Immune Pharmaceuticals?

Shares of IMNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Pharmaceuticals' stock price today?

One share of IMNP stock can currently be purchased for approximately $0.0185.

What is Immune Pharmaceuticals' official website?

The official website for Immune Pharmaceuticals is http://www.immunepharmaceuticals.com.

How can I contact Immune Pharmaceuticals?

Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected]


MarketBeat Community Rating for Immune Pharmaceuticals (NASDAQ IMNP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel